These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

294 related articles for article (PubMed ID: 26140615)

  • 1. RNA interference technology with emphasis on delivery vehicles-prospects and limitations.
    Prabha S; Vyas R; Gupta N; Ahmed B; Chandra R; Nimesh S
    Artif Cells Nanomed Biotechnol; 2016 Sep; 44(6):1391-9. PubMed ID: 26140615
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Nanoparticle-siRNA: A potential cancer therapy?
    Young SW; Stenzel M; Yang JL
    Crit Rev Oncol Hematol; 2016 Feb; 98():159-69. PubMed ID: 26597018
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Toxicogenomics of non-viral drug delivery systems for RNAi: potential impact on siRNA-mediated gene silencing activity and specificity.
    Akhtar S; Benter I
    Adv Drug Deliv Rev; 2007 Mar; 59(2-3):164-82. PubMed ID: 17481774
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Lipid nanoparticles for short interfering RNA delivery.
    Leung AK; Tam YY; Cullis PR
    Adv Genet; 2014; 88():71-110. PubMed ID: 25409604
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Nanoparticles for siRNA-Based Gene Silencing in Tumor Therapy.
    Babu A; Muralidharan R; Amreddy N; Mehta M; Munshi A; Ramesh R
    IEEE Trans Nanobioscience; 2016 Dec; 15(8):849-863. PubMed ID: 28092499
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Bio-inspired materials in drug delivery: Exploring the role of pulmonary surfactant in siRNA inhalation therapy.
    De Backer L; Cerrada A; Pérez-Gil J; De Smedt SC; Raemdonck K
    J Control Release; 2015 Dec; 220(Pt B):642-50. PubMed ID: 26363301
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Research progress on the development of the strategies for siRNAs delivery in vivo].
    Tang D; Mao A
    Sheng Wu Yi Xue Gong Cheng Xue Za Zhi; 2012 Aug; 29(4):775-9. PubMed ID: 23016434
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Quaternized starch-based carrier for siRNA delivery: from cellular uptake to gene silencing.
    Amar-Lewis E; Azagury A; Chintakunta R; Goldbart R; Traitel T; Prestwood J; Landesman-Milo D; Peer D; Kost J
    J Control Release; 2014 Jul; 185():109-20. PubMed ID: 24794893
    [TBL] [Abstract][Full Text] [Related]  

  • 9. RNA interference by nanofiber-based siRNA delivery system.
    Cao H; Jiang X; Chai C; Chew SY
    J Control Release; 2010 Jun; 144(2):203-12. PubMed ID: 20138939
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Overcoming the Challenges of siRNA Delivery: Nanoparticle Strategies.
    Shajari N; Mansoori B; Davudian S; Mohammadi A; Baradaran B
    Curr Drug Deliv; 2017; 14(1):36-46. PubMed ID: 27538460
    [TBL] [Abstract][Full Text] [Related]  

  • 11. RNA interference and the use of small interfering RNA to study gene function in mammalian systems.
    Bantounas I; Phylactou LA; Uney JB
    J Mol Endocrinol; 2004 Dec; 33(3):545-57. PubMed ID: 15591019
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A biomimetic nanovector-mediated targeted cholesterol-conjugated siRNA delivery for tumor gene therapy.
    Ding Y; Wang W; Feng M; Wang Y; Zhou J; Ding X; Zhou X; Liu C; Wang R; Zhang Q
    Biomaterials; 2012 Dec; 33(34):8893-905. PubMed ID: 22979990
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Recent developments in nanoparticle-based siRNA delivery for cancer therapy.
    Lee JM; Yoon TJ; Cho YS
    Biomed Res Int; 2013; 2013():782041. PubMed ID: 23844368
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Therapeutic application of RNA interference for hepatitis C virus.
    Watanabe T; Umehara T; Kohara M
    Adv Drug Deliv Rev; 2007 Oct; 59(12):1263-76. PubMed ID: 17822803
    [TBL] [Abstract][Full Text] [Related]  

  • 15. RNAi in functional genomics.
    Scherr M; Eder M
    Curr Opin Mol Ther; 2004 Apr; 6(2):129-35. PubMed ID: 15195923
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Photocontrolled Intracellular RNA Delivery Using Nanoparticles or Carrier-Photosensitizer Conjugates.
    Watanabe K; Ohtsuki T
    Prog Mol Biol Transl Sci; 2016; 139():101-19. PubMed ID: 26970192
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Co-delivery of VEGF and Bcl-2 dual-targeted siRNA polymer using a single nanoparticle for synergistic anti-cancer effects in vivo.
    Lee SJ; Yook S; Yhee JY; Yoon HY; Kim MG; Ku SH; Kim SH; Park JH; Jeong JH; Kwon IC; Lee S; Lee H; Kim K
    J Control Release; 2015 Dec; 220(Pt B):631-41. PubMed ID: 26307351
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Budding Alliance of Nanotechnology in RNA Interference Therapeutics.
    Kumawat A; Dapse P; Kumar N; Mishra DK; Maheshwari R; Bhattacharya P; Tekade RK
    Curr Pharm Des; 2018; 24(23):2632-2643. PubMed ID: 30084328
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Hydroxyapatite nanoparticles modified by branched polyethylenimine are effective non-viral vectors for siRNA transfection of hepatoma cells in vitro.
    Xu XL; Yang HY; Ou B; Lin SD; Wu H; He W; Jiang QC; Luo BM; Li GP
    Int J Oncol; 2015 May; 46(5):2138-42. PubMed ID: 25760143
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A novel siRNA validation system for functional screening of effective RNAi targets in mammalian cells and development of a derivative lentivirus delivery system.
    Huang G; Gao Q; Zhao Y; Dong Z; Li T; Guan X; Jiang J
    Gene; 2015 Mar; 558(2):278-86. PubMed ID: 25550051
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.